Axcelis price target lowered to $90 from $100 at BofA

BofA analyst Duksan Jang lowered the firm’s price target on Axcelis (ACLS) to $90 from $100 and keeps an Underperform rating on the shares. The firm, which is waiting for clearer signs of recovery, lowered its calendar year 2026-28 sales estimates by 5%-8% and EPS estimates by 9%-16%.